About the Company
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CLRB News
Cellectar Biosciences to Present at the 36th Annual Roth Conference
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and ...
Tierra Biosciences nabs $11 million to create new AI-guided proteins
Scientific breakthroughs have accelerated the pace at which new pharmaceuticals are being developed. Tierra Biosciences ...
IO Biotech GAAP EPS of -$0.40 misses by $0.02
Q4 GAAP EPS of -$0.40 misses by $0.02. Ended 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into ...
Loading the latest forecasts...